Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology for multiple indications in companion animals. The two companies have agreed to broaden their joint efforts in several key areas — including shared clinic relationships, licensing coordination, and manufacturing optimization. These initiatives build upon prior collaborations involving device classification, dev ...

Core Points - Vivos Inc. has authorized the formation of a wholly owned subsidiary in India named Vivos Scientific India LLP, and is in the process of obtaining formal approvals from the Indian government [1] - The establishment of the subsidiary reflects Vivos's long-term commitment to the Indian market, aiming to set up its first international manufacturing center for RadioGel and IsoPet, and to expand developmental animal testing and commercial treatments in India [2] - Vivos has initiated first-in-human trials in India and is pursuing additional approvals for expanded human trials from the Drug Controller General of India (DCGI), which are believed to support the IDE process with the FDA [2] Company Strategy - The company plans to include immediate post-treatment PET full-body scans in the next phase of human trials in India to validate the safety profile of RadioGel, based on feedback from the FDA [2]

Core Points - Vivos Inc. has received authorization to establish a wholly owned subsidiary in India named Vivos Scientific India LLP, and is in the process of obtaining formal approvals from the Indian government [1] - The establishment of the subsidiary reflects Vivos Inc.'s long-term commitment to the Indian market, aiming to set up an international manufacturing center for RadioGel and IsoPet, and to expand developmental animal testing and commercial treatments for humans and animals in India [2] - Vivos Inc. has initiated first-in-human trials in India and is pursuing approval from the Drug Controller General of India (DCGI) for expanded human trials, which are expected to support the IDE process with the FDA [2] Company Strategy - The company plans to include immediate post-treatment PET full-body scans in the next phase of human trials in India to validate the safety profile of RadioGel, based on feedback from the FDA [2]

Kennewick, WA, April 23, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a leader in innovative cancer therapies, announced today a record-breaking first quarter for its IsoPet Animal Cancer Division. The company's patented Precision Radionuclide Therapy (PRnT) treated an unprecedented number of pets in Q1 2025, marking a 150% year-over-year increase in treatment volume. This milestone underscores IsoPet's growing role as a transformative, non-invasive solution for veterinary oncology. Q1 2025 Highlights ...